Diagnose Parkinsons disease with colonoscopy
- Trial ID
- NCT07204652
- Official Title
- Detection of Phosphorylated Alpha-synuclein Through Routine Colonoscopy to Diagnose Parkinson's Disease and Related Disorders
- Goal
- Diagnose Parkinsons disease with colonoscopy
- Status
- RECRUITING
- Sponsor
- CND Life Sciences
- Study Type
- OBSERVATIONAL
- Enrollment
- 20 participants
- Conditions
- PARKINSON DISEASE (Disorder), Parkinson, Parkinson's Disease and Parkinsonism, Parkinson Disease
- Interventions
- No Intervention: Observational Cohort
Plain-Language Summary
The goal is to see whether phosphorylated alpha-synuclein, the abnormal form of the protein linked to Parkinson's, can be detected in routine colon biopsies and help diagnose Parkinson's disease and related disorders. During a routine colonoscopy small tissue samples are taken and tested for phosphorylated alpha-synuclein, the disease-related protein that can accumulate in gut nerve cells, so researchers can learn if gut testing could support diagnosis without changing Parkinson's medications. They are looking for adults 40 to 99 with a confirmed Parkinson's diagnosis by UKPDS Brain Bank Criteria who are already scheduled for routine colonoscopy, excluding people on anticoagulants (single-agent aspirin up to 325 mg or clopidogrel 75 mg may be allowed), or with colon cancer, recent GI illness or surgery, pregnancy, or significant cognitive or decisional impairment.
Locations
- Oregon Health & Science University, Portland, Oregon, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying No Intervention: Observational Cohort. The goal is to see whether phosphorylated alpha-synuclein, the abnormal form of the protein linked to Parkinson's, can be detected in routine colon biopsies and help diagnose Parkinson's disease and related disorders. During a routine colonoscopy small tissue samples are taken and tested for phosphorylated alpha-synuclein, the disease-related protein that can accumulate in gut nerve cells, so researchers can learn if gut testing could support diagnosis without changing Parkinson's medications. They are looking for adults 40 to 99 with a confirmed Parkinson's diagnosis by UKPDS Brain Bank Criteria who are already scheduled for routine colonoscopy, excluding people on anticoagulants (single-agent aspirin up to 325 mg or clopidogrel 75 mg may be allowed), or with colon cancer, recent GI illness or surgery, pregnancy, or significant cognitive or decisional impairment.
- Who can participate?
- Participants must be between 40 Years and 99 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.